ATE230260T1 - Therapeutische abgabesysteme und verfahren für ihre verwendung - Google Patents

Therapeutische abgabesysteme und verfahren für ihre verwendung

Info

Publication number
ATE230260T1
ATE230260T1 AT94931827T AT94931827T ATE230260T1 AT E230260 T1 ATE230260 T1 AT E230260T1 AT 94931827 T AT94931827 T AT 94931827T AT 94931827 T AT94931827 T AT 94931827T AT E230260 T1 ATE230260 T1 AT E230260T1
Authority
AT
Austria
Prior art keywords
approximately
c2h4o
methods
c3h6o
integer
Prior art date
Application number
AT94931827T
Other languages
English (en)
Inventor
R Martin Emanuele
Hameedsulthan S Allaudeen
Konstantin G Kousoulas
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Application granted granted Critical
Publication of ATE230260T1 publication Critical patent/ATE230260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94931827T 1993-10-15 1994-10-12 Therapeutische abgabesysteme und verfahren für ihre verwendung ATE230260T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13827193A 1993-10-15 1993-10-15
PCT/US1994/011594 WO1995010265A1 (en) 1993-10-15 1994-10-12 Therapeutic delivery compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE230260T1 true ATE230260T1 (de) 2003-01-15

Family

ID=22481270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931827T ATE230260T1 (de) 1993-10-15 1994-10-12 Therapeutische abgabesysteme und verfahren für ihre verwendung

Country Status (9)

Country Link
EP (1) EP0723440B1 (de)
JP (1) JP3819422B2 (de)
KR (1) KR100218140B1 (de)
AT (1) ATE230260T1 (de)
AU (1) AU8076494A (de)
DE (1) DE69431959T2 (de)
DK (1) DK0723440T3 (de)
ES (1) ES2189808T3 (de)
WO (1) WO1995010265A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (de) 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100360827B1 (ko) 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
EP1278551A2 (de) 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
EP1232758A1 (de) * 2001-02-19 2002-08-21 Aventis Pasteur Polynukleotid-Formulierung für verbesserte intrazellulare Übertragung
DK1456377T3 (da) 2001-12-20 2019-09-23 Merck Sharp & Dohme Syn3-sammensætninger og fremgangsmåder
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
ES2649165T3 (es) 2013-02-05 2018-01-10 The Board Of Trustees Of The Leland Stanford Junior University CD47 terapias dirigidas para el tratamiento de enfermedades infecciosas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308458A1 (de) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg Verfahren zur adjuvierung von vaccinen
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
WO1992016484A1 (en) * 1991-03-19 1992-10-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy

Also Published As

Publication number Publication date
KR100218140B1 (ko) 1999-09-01
EP0723440A1 (de) 1996-07-31
JPH09503788A (ja) 1997-04-15
JP3819422B2 (ja) 2006-09-06
DK0723440T3 (da) 2003-02-24
ES2189808T3 (es) 2003-07-16
EP0723440A4 (de) 1997-06-11
EP0723440B1 (de) 2003-01-02
KR960704534A (ko) 1996-10-09
AU8076494A (en) 1995-05-04
WO1995010265A1 (en) 1995-04-20
DE69431959T2 (de) 2003-11-06
DE69431959D1 (de) 2003-02-06

Similar Documents

Publication Publication Date Title
ATE230260T1 (de) Therapeutische abgabesysteme und verfahren für ihre verwendung
EP0677056B1 (de) Olionukleotidalkylphosphonate und -phosphonothioate
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
US20020137718A1 (en) Nucleozymes
KR100310277B1 (ko) 뼈 형성 촉진용 저분자량 하이알루론산의 제조
BR9106729A (pt) Composto,processos para inibir a degradacao por nuclease de compostos e para estabilizar sequencias de nicleotideos ou oligonucleosideos,composicao utilizavel para inibir expressao de genes e processo para inibir expressao de genes em um mamifero necessitando de tal tratamento
BR9611692A (pt) Agentes de limpeza para superfícies duras
KR920702383A (ko) 치료제의 방출을 조절하는데 유용한 생부식성 중합체
JP2004536103A5 (de)
MX9406552A (es) Metodo, composiciones y dispositivos para la admi nistracion de polinucleotidos desnudos que codifi can peptidos biologicamente activos.
US6040159A (en) TNF-α ribozymes and derivatives capable of decreasing degradation of MRNA in vivo
CA2377290A1 (en) Utilization of a highly fluorinated oligomeric alkane in ophthalmology
WO2002062767A1 (fr) Nouveaux derives de quinazoline
CA2132265C (en) Anti-sense oligonucleotides against hsv-1, and their preparation
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
HUP0103751A2 (hu) Epesavval helyettesített fenilalkenoilguanidinek, valamint e vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására
WO1996019478A1 (en) 6'-substituted carbocyclic nucleosides
KR20200024793A (ko) 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
WO2001098522A3 (en) Positively-charged peptide nucleic acid analogs with improved properties
CA2174122A1 (en) Therapeutic delivery compositions and methods of use thereof
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
EP0739901A3 (de) Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
EP0129891A3 (de) Chinazolinon-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
JP2023501246A (ja) ベータＥＮａＣの発現を阻害するＲＮＡｉ剤、その組成物および使用方法
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0723440

Country of ref document: EP

REN Ceased due to non-payment of the annual fee